Ministère de l'Emploi et de la Solidarité sociale
Lois et règlements codifiés Lois codifiées Règlements codifiés Lois et règlements annuels Lois annuelles Règlements annuels Information complémentaire L’Éditeur officiel du Québec Quoi de neuf? Note d’information Politique du ministre de la Justice Lois : Modifications Lois : Dispositions non en vigueur Lois : Entrées en vigueur Lois annuelles : Versions PDF depuis 1996 Règlements : Modifications Règlements annuels : Versions PDF depuis 1996 Décisions des tribunaux

P-12, r. 6 - Regulation respecting the medications that a podiatrist who obtained a permit to practise before 1976 may administer or prescribe

Table des matières
Occurrences0
Version courante
Texte complet
À jour au 1er mai 2020
Ce document a valeur officielle.
chapter P-12, r. 6
Regulation respecting the medications that a podiatrist who obtained a permit to practise before 1976 may administer or prescribe
Podiatry Act
(chapter P-12, s. 12).
O.C. 1057-91; O.C. 173-2020, s. 1.
1. A podiatrist who obtained a permit to practise before 1 January 1976 may, in the practice of the profession, administer or prescribe the medications listed in Schedule I.
O.C. 1057-91, s. 1; O.C. 142-2003, s. 1; O.C. 173-2020, s. 2.
2. Until 1 May 2021, a podiatrist to who section 1 does not apply, who obtained a permit to practise before 1 May 2020 and who has not yet undergone the training provided for in the Regulation respecting the medications that a podiatrist may administer or prescribe (chapter P-12, r. 6.1) may, in the practice of the profession, administer or prescribe the medications listed in Schedules I and II.
O.C. 1057-91, s. 2; O.C. 142-2003, s. 2; O.C. 173-2020, s. 2.
3. (Omitted).
O.C. 1057-91, s. 3.
SCHEDULE I
(ss. 1 and 2)
1. Any medication listed below, subject to the restrictions indicated:
MedicationsRestrictions
Aluminium and its salts 
Amcinonide 
Anthralin 
Silver sulfadiazine 
Bacitracin and its salts 
Beclomethasone and its salts 
Benzalkonium 
Benzocaine 
Betamethasone dipropionate 
Betamethasone valerate 
Bupivacaine and its saltsPharmaceutical form intended for administration by injection for local use only
Calcipotriol 
Calcitriol 
Camphor 
Cantharidin 
Cetirizine hydrochloride 
Chlorhexidine and its salts 
Ciclopirox olamine 
Cinchocaine (dibucaine) 
Clioquinol 
Clobetasol proprionate 
Clotrimazole 
Cyproheptadine hydrochloride 
Desonide 
Desoximetasone 
DiphenhydraminePharmaceutical form intended for oral and topical administration
Efinaconazole 
Epinephrine (adrenaline) 
ErythromycinPowder extemporaneous mixture or topical preparation
Ethyl chloride 
Fluocinolone acetonide 
Fluocinode 
Formalin 
Framycetin sulfate 
Fusidic acid 
Gentamicin sulfate 
Mineral tar 
Vegetal tar 
Gramicidin 
Hexachlorophene 
Hydrocortisone and its saltsPharmaceutical form intended for topical administration
Hydroxyzine hydrochloridePharmaceutical form intended for oral administration
Povidone iodine 
KetoconazolePharmaceutical form intended for topical administration
Lactic acid 
Lidocaine and its saltsPharmaceutical form intended for administration by injection for local use only
LoratadinePharmaceutical form intended for oral administration
LorazepamPharmaceutical form intended for oral and sublingual administration
Quantity limited to 4 tablets
MepivacainePharmaceutical form intended for administration by injection for local use only
Methylpolysiloxanes (dimethicone) 
Methylprednisolone acetate 
Miconazole nitrate 
Mometasone furorate 
Mupirocin 
Neomycin sulfate 
Nystatin, its salts and derivativesPharmaceutical form intended for topical administration
Dressings and products associated with the treatment of wounds and alterations of the skin and teguments 
Phenol 
Podophyllin 
Polymyxin B sulfate 
Pramoxine 
Promethazine hydrochloride 
Resorcinol and its salts 
Triethanolamine salicylate 
Salicylic acid 
Silicone (dimethicone) 
Sulphur colloidal 
Sulphur precipitate 
Sulphur sublimate 
Tazarotene 
Tolnaftate 
Triamcinolone acetonidePharmaceutical form intended for topical administration
Trichloroacetic acid 
Trimeprazine tartrate 
UreaPharmaceutical form intended for topical administration, with a concentration of 40% or less
2. Any other medication intended for topical or oral administration that is not listed in Schedule I of the Regulation respecting the terms and conditions for the sale of medications (chapter P-10, r. 12).
3. Any combination of medications of this Schedule, subject to the applicable restrictions.
O.C. 1057-91, Sch. I; O.C. 142-2003, s. 3; O.C. 522-2005, s. 1; O.C. 173-2020, s. 3.
NOTE: Medications without specification are intended for topical application.

________________________________________________________________

Substances Specification
________________________________________________________________

Acetaminophen Pharmaceutical form intended
for oral and rectal administration

Acetaminophen and Pharmaceutical form intended
codeine for oral administration
(in combination) containing 30 mg or less of
codeine per tablet

Acetic, Quantity limited to 24 tablets/
glacial acid 72 hours

Acetylsalicyclic Pharmaceutical form intended
acid for oral administration

Aluminium and its salts

Almond, sweet oil

Amcinonide Quantity limited for 30 days

Anthralin (dithranol)

Silver nitrate

Silver sulfadiazine

Colloidal oatmeal

Bacitracin and its salts

Beclomethasone and its salts

Benzalkonium

Benzocaine

Betamethasone Pharmaceutical forms
acetate and intended for administration by
phosphate intramuscular or intradermal
injection

Betamethasone benzoate

Betamethasone Quantity limited for 30 days
dipropionate

Betamethasone valerate

Bleomycin sulfate Pharmaceutical form injectable in
the plantar lesion without
exceeding 0.8 units up to a maximum
of 5 units per treatment

Bupivacaine and Pharmaceutical form intended for
its salts administration by injection for
local use only

Calcipotriol

Camphor

Cantharidin

Capsaicin

Celecoxib Pharmaceutical form intended for
oral administration

Quantity limited for 30 days

Cetirizine Pharmaceutical form intended for
hydrochloride oral administration

Chlorhexidine and its salts

Chlorprocaine Pharmaceutical form intended for
hydrochloride administration by injection for
local use only

Ciclopirox olamine

Cinchocaine

Clioquinor
(iodochlorhydroxyquin)

Clobetasol Quantity limited for 30 days
proprionate

Clobetasone butyrate

Clotrimazole

Dakin’s solution

Desonide

Desoximetasone Quantity limited for 30 days

Dichloracetic acid

Diclofenac, Pharmaceutical form intended
potassic and sodic for oral administration

Quantity limited for 30 days

Diflucortolone Quantity limited for 30 days
valerate

Dyphenhydramine Pharmaceutical forms intended
for oral administration and
administration by intramuscular,
subcutaneous or intradermal
injection



Epinephrine Pharmaceutical forms for the
(adrenaline) emergency treatment of
anaphylactic reactions in the
form of auto-injector or vial

Pharmaceutical form associated
with local anaesthetics

Erythromycin

Ethyl chloride

Fluocinolone Quantity limited for 30 days
acetonide

Fluocinode Quantity limited for 30 days

5-fluorouracil 5% pharmaceutical form intended
for topical application in the
case of plantar warts resistant to
first-line treatments

Formaline

Framycetin sulfate

Fusidic acid

Gentamicin sulfate

Gentian, violet

Mineral and vegetal tar

Gramicidin

Hexachlorophene

Mineral oil

Hydrocortisone and its salts

Hydroxyzine Pharmaceutical form intended for
hydrochloride oral administration

Ibuprofen Pharmaceutical form intended for
oral administration

Quantity limited for 30 days

Povidone iodine

Ketoconazole

Lactic acid

Lanolin

Lidocaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only

Loratadine Pharmaceutical form intended for
oral administration

Lorazepam Pharmaceutical form intended for
oral and sublingual administration
in anticipation of surgical
procedures, containing 0.5 mg or
1 mg of Lorazepam per tablet

Quantity limited to 4 tablets

Menthol

Mepivacaine Pharmaceutical form intended for
administration by injection
for local use only

Methylpolysiloxanes

Methylprednisolone Pharmaceutical forms intended for
acetate topical application and
administration by injection for
local use only
Miconazole nitrate

Mometasone furorate

Mupirocin

Naproxen Pharmaceutical form intended for
oral administration

Quantity limited for 30 days

Neomycin sulfate

Nystatin

Phenol

Podophyllin

Polymyxin B sulfate

Pramoxine

Prilocaine Pharmaceutical forms intended for
topical application and
administration by injection for
local use only

Procaine Pharmaceutical form intended for
administration by injection for
local use only

Resorcinol and its salts

Methyl salicylate

Triethanolamine salicylate

Salicylic acid

Silicone

Sulphur, colloidal,
precipitate or sublimate

Tazarotene

Terbinafine

Tetracaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only


Tolnaftate

Triamcinolone Quantity limited for 30 days
acetonide

Triamcinolone Pharmaceutical forms intended for
hexacetonide administration by intramuscular or
intradermal injection
Quantity limited for 30 days

Trichloroacetic acid

Urea Pharmaceutical form intended for
topical application, with a
concentration of 30% or less

White petroleum jelly

Zinc oxide
O.C. 142-2003, s. 3; O.C. 522-2005, s. 2; O.C. 173-2020, s. 4.
REFERENCES
O.C. 1057-91, 1991 G.O. 2, 3231
O.C. 142-2003, 2003 G.O. 2, 1013
O.C. 522-2005, 2005 G.O. 2, 1872
O.C. 173-2020, 2020 G.O. 2, 776
© Gouvernement du Québec